European knowledge base for researchers and industry
The EU-NCL aims at fostering innovation in Nanomedicine by providing access to state of the art full characterisation of nanomaterials intended for medical applications, developed by public labs, spin –offs and innovative SMEs. The EU-NCL shall also serve as a European knowledge base for researchers and industry ensuring that European knowledge is documented in Europe for the benefit of the European economy, healthcare systems and patients.
The EU-NCL shall provide a comprehensive set of characterisation tests (physical, chemical, in vitro and in vivo biological properties) allowing researchers and SMEs to better understand or predict the clinical in vivo effects of their medical nanomaterials. On top of that, a full characterisation is required by regulation agencies before approval of any tests on human beings.. The knowledge base to be developed by EU-NCL will help the European Medicines Agency (EMA) or other relevant agencies (e.g. notified body) to adapt the current regulation and approval process to Nanomedicine products. Further links with EURAMET (standardisation of analytical methods of nanomedical nanomaterials) as well as with the nanomaterials eco-toxicity initiative will be implemented in order to share some analytical methods and equipment.
The EU-NCL will also have a strategic and political role in helping newcomers, like spin-offs or SMEs, in getting an easy access to nanocharacterisation and further to prepare their submission for product approval.
European Nanomedicine Characterisation Laboratory (EU-NCL)